Viavi (VIAV) Form 4: Director Richard Burns awarded 6,768 RSUs
Rhea-AI Filing Summary
Richard John Burns, a director of Viavi Solutions Inc. (VIAV), was granted 6,768 restricted stock units (RSUs) on 08/28/2025. The award carries a $0 purchase price and results in 6,768 shares of common stock beneficially owned following the transaction, held directly. The RSUs vest on the earlier of the one-year anniversary of the grant or the company’s next annual meeting of stockholders, and the RSUs have no expiration date. The Form 4 was signed by Donna T. Rossi as attorney-in-fact on 08/29/2025 and was filed as a single reporting person filing.
Positive
- Grant of 6,768 RSUs increases director alignment with shareholders by converting compensation into equity
- Vesting schedule is time-based (earlier of one year or next annual meeting), encouraging retention
- No expiration on RSUs provides straightforward mechanics for the award
Negative
- None.
Insights
TL;DR: Routine director compensation: a grant of 6,768 RSUs with standard vesting tied to time or the next annual meeting.
This Form 4 documents a customary equity award to a director, providing alignment with shareholder interests through ownership rather than cash. The grant vests on the earlier of one year or the next annual meeting, which is typical for non-executive director awards to encourage retention and continued service. The award carries no exercise price and no expiration on the RSUs, consistent with restricted stock unit mechanics rather than option grants. This filing does not disclose any sale or purchase for cash, change in control provisions, or accelerated vesting conditions beyond the stated vesting schedule.
TL;DR: Non-material insider transaction: issuance of 6,768 RSUs to a director, increasing direct beneficial ownership by the same amount.
From an investor-impact perspective, this is a routine insider grant for compensation purposes and is unlikely to be material to VIAV’s capital structure or valuation given the modest share count disclosed. The Form 4 confirms direct ownership of the underlying common shares following grant and provides clarity on vesting timing and lack of expiration. No cash consideration, dispositions, or derivative activity are reported in this filing.